4.7 Review

PI3K: A potential therapeutic target for cancer

Journal

JOURNAL OF CELLULAR PHYSIOLOGY
Volume 227, Issue 7, Pages 2818-2821

Publisher

WILEY
DOI: 10.1002/jcp.23038

Keywords

-

Funding

  1. Scientific Research Program of Shanghai [11ZR142400]
  2. Funding of Xinhua Hospital [11QYJ010]

Ask authors/readers for more resources

Phosphatidylinositol 3-kinase (PI3K), one member of lipid kinase family, has been demonstrated to play a key role in regulating cell proliferation, adhesion, survival, and motility. Recent studies indicate that PI3K related signaling pathway is one of the most commonly activated pathways in human cancers. Accordingly, pharmacological inhibition of key nodes in this signaling cascade has been a focus in developmental therapeutics. To date, Inhibitors targeting PI3K or nodes in this pathway, AKT and mTOR, are best studied and have reached clinical trials. In this review, we will focus on recent progress on understanding of PI3Ks signaling pathway and the development of PI3K inhibitors. J. Cell. Physiol. 227: 28182821, 2012. (C) 2011 Wiley Periodicals, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available